NFL Biosciences S.A.
ALNFL.PA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.7M
Close$
$0.11
67.2% downside
Current Fair Value
67.2% downsideOvervalued by 67.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.70 Million |
|---|---|
| Enterprise Value | $4.53 Million |
| Earnings per Share | $-0.26 |
| Beta | 1.15 |
| Outstanding Shares | 12,670,000 |
Return
| Return on Equity | -2023.26% |
|---|---|
| Return on Assets | -169.08% |
| Return on Invested Capital | -1038.32% |
Valuation & Multiples
| P/E Ratio | -1.88 |
|---|---|
| PEG | 12.21 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 2.7 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 29, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About NFL Biosciences S.A.
4 employees
CEO: Bruno Lafont
Established in 2006 and headquartered in Castelnau-le-Lez, France, NFL Biosciences S.A. is a biotechnology enterprise dedicated to pioneering natural remedies for addiction cessation, particularly for individuals seeking to quit smoking....